219 related articles for article (PubMed ID: 34773060)
21. Itraconazole vs. posaconazole for antifungal prophylaxis in patients with acute myeloid leukemia undergoing intensive chemotherapy: A retrospective study.
Copley MS; Waldron M; Athans V; Welch SC; Brizendine KD; Cober E; Siebenaller C
Int J Antimicrob Agents; 2020 Mar; 55(3):105886. PubMed ID: 31926286
[TBL] [Abstract][Full Text] [Related]
22. Invasive Fungal Infections in Immunocompromised Children: Novel Insight Following a National Study.
Olivier-Gougenheim L; Rama N; Dupont D; Saultier P; Leverger G; AbouChahla W; Paillard C; Gandemer V; Theron A; Freycon C; Pluchart C; Blouin P; Pellier I; Thouvenin-Doulet S; Desplantes C; Ducassou S; Oudot C; Rouger-Gaudichon J; Cheikh N; Poiree M; Schneider P; Plat G; Contet A; Rialland F; Gouache E; Brethon B; Bertrand Y; Domenech C
J Pediatr; 2021 Sep; 236():204-210. PubMed ID: 33991540
[TBL] [Abstract][Full Text] [Related]
23. Invasive fungal diseases in patients with new diagnosed acute lymphoblastic leukaemia.
Gründahl M; Wacker B; Einsele H; Heinz WJ
Mycoses; 2020 Oct; 63(10):1101-1106. PubMed ID: 32738006
[TBL] [Abstract][Full Text] [Related]
24. Does High-Dose Cytarabine Cause More Fungal Infection in Patients With Acute Myeloid Leukemia Undergoing Consolidation Therapy: A Multicenter, Prospective, Observational Study in China.
Wang L; Hu J; Sun Y; Huang H; Chen J; Li J; Ma J; Li J; Liang Y; Wang J; Li Y; Yu K; Hu J; Jin J; Wang C; Wu D; Xiao Y; Huang X
Medicine (Baltimore); 2016 Jan; 95(4):e2560. PubMed ID: 26825897
[TBL] [Abstract][Full Text] [Related]
25. Risk of invasive fungal infections in patients with high-risk MDS and AML receiving hypomethylating agents.
Kim GYG; Burns J; Freyer CW; Hamilton KW; Frey NV; Gill SI; Hexner EO; Luger SM; Mangan JK; Martin ME; McCurdy SR; Perl AE; Porter DL; Schuster MG; Stadtmauer EA; Loren AW
Am J Hematol; 2020 Jul; 95(7):792-798. PubMed ID: 32242967
[TBL] [Abstract][Full Text] [Related]
26. Isavuconazonium or posaconazole for antifungal prophylaxis in patients with acute myeloid leukemia.
White O; Kennedy E; Huckabee JB; Rogers E; LeBlanc TW; Dillon M; Li Z; Hanna D
J Oncol Pharm Pract; 2024 Apr; 30(3):527-534. PubMed ID: 37186784
[TBL] [Abstract][Full Text] [Related]
27. Risk factors for breakthrough invasive fungal infection during secondary prophylaxis.
Cornely OA; Böhme A; Reichert D; Reuter S; Maschmeyer G; Maertens J; Buchheidt D; Paluszewska M; Arenz D; Bethe U; Effelsberg J; Lövenich H; Sieniawski M; Haas A; Einsele H; Eimermacher H; Martino R; Silling G; Hahn M; Wacker S; Ullmann AJ; Karthaus M;
J Antimicrob Chemother; 2008 Apr; 61(4):939-46. PubMed ID: 18272515
[TBL] [Abstract][Full Text] [Related]
28. Epidemiology of invasive fungal diseases in adults with newly diagnosed acute myeloid leukemia.
Miranti E; Ho DY; Enriquez K; Subramanian AK; Medeiros BC; Epstein DJ
Leuk Lymphoma; 2022 Sep; 63(9):2206-2212. PubMed ID: 35410569
[TBL] [Abstract][Full Text] [Related]
29. Incidence and outcome of invasive fungal disease after front-line intensive chemotherapy in patients with acute myeloid leukemia: impact of antifungal prophylaxis.
Rodríguez-Veiga R; Montesinos P; Boluda B; Lorenzo I; Martínez-Cuadrón D; Salavert M; Pemán J; Calvillo P; Cano I; Acuña E; Villalba A; Piñana JL; Sanz J; Solves P; Senent L; Vicente A; Sempere A; Cervera J; Barragán E; Jarque I; Torres A; Sanz MA; Sanz GF
Ann Hematol; 2019 Sep; 98(9):2081-2088. PubMed ID: 31240471
[TBL] [Abstract][Full Text] [Related]
30. Prevalence and Predictors of Invasive Fungal Infections in Children with Persistent Febrile Neutropenia Treated for Acute Leukemia - A Prospective Study.
Kumar J; Singh A; Seth R; Xess I; Jana M; Kabra SK
Indian J Pediatr; 2018 Dec; 85(12):1090-1095. PubMed ID: 29956075
[TBL] [Abstract][Full Text] [Related]
31. 'Real-life' analysis of the role of antifungal prophylaxis in preventing invasive aspergillosis in AML patients undergoing consolidation therapy: Sorveglianza Epidemiologica Infezioni nelle Emopatie (SEIFEM) 2016 study.
Del Principe MI; Dragonetti G; Verga L; Candoni A; Marchesi F; Cattaneo C; Delia M; Potenza L; Farina F; Ballanti S; Decembrino N; Castagnola C; Nadali G; Fanci R; Orciulo E; Veggia B; Offidani M; Melillo L; Manetta S; Tumbarello M; Venditti A; Busca A; Aversa F; Pagano L;
J Antimicrob Chemother; 2019 Apr; 74(4):1062-1068. PubMed ID: 30649413
[TBL] [Abstract][Full Text] [Related]
32. Prophylactic administration of voriconazole with two different doses for invasive fungal infection in children and adolescents with acute myeloid leukemia.
Sano H; Kobayashi R; Hori D; Kishimoto K; Suzuki D; Yasuda K; Kobayashi K
J Microbiol Immunol Infect; 2018 Apr; 51(2):260-266. PubMed ID: 27329132
[TBL] [Abstract][Full Text] [Related]
33. Breakthrough invasive fungal infection in patients with myeloid malignancy receiving posaconazole tablet prophylaxis: Clinical features, risk factors, and posaconazole profiles.
Hong JY; Kang CI; Yang J; Ko JH; Huh K; Cho SY; Chung DR; Jung CW; Peck KR
Med Mycol; 2023 Apr; 61(5):. PubMed ID: 37120735
[TBL] [Abstract][Full Text] [Related]
34. [Primary antifungal prophylaxis with posaconazole plays a pivotal role during chemotherapy of acute myeloid leukemia].
Gong BF; Liu YT; Zhang GJ; Wei SN; Li Y; Liu KQ; Gong XY; Zhao XL; Qiu SW; Gu RX; Lin D; Wei H; Zhou CL; Liu BC; Wang Y; Mi YC; Wang JX
Zhonghua Xue Ye Xue Za Zhi; 2017 Jun; 38(6):528-531. PubMed ID: 28655098
[No Abstract] [Full Text] [Related]
35. High Incidences of Invasive Fungal Infections in Acute Myeloid Leukemia Patients Receiving Induction Chemotherapy without Systemic Antifungal Prophylaxis: A Prospective Observational Study in Taiwan.
Tang JL; Kung HC; Lei WC; Yao M; Wu UI; Hsu SC; Lin CT; Li CC; Wu SJ; Hou HA; Chou WC; Huang SY; Tsay W; Chen YC; Chen YC; Chang SC; Ko BS; Tien HF
PLoS One; 2015; 10(6):e0128410. PubMed ID: 26061179
[TBL] [Abstract][Full Text] [Related]
36. Evaluation of the implementation rate of primary antifungal prophylaxis and the prognosis of invasive fungal disease in acute leukemia patients in China.
Xu XH; Zhang L; Cao XX; Li J; Zhang W; Zhu TN; Cai HC; Chen M; Han X; Yang C; Han B; Zhang Y; Zhuang JL; Zhou DB; Duan MH
J Infect Chemother; 2017 Jun; 23(6):360-367. PubMed ID: 28341518
[TBL] [Abstract][Full Text] [Related]
37. Primary prophylaxis of invasive fungal infections in patients with haematological malignancies: 2017 update of the recommendations of the Infectious Diseases Working Party (AGIHO) of the German Society for Haematology and Medical Oncology (DGHO).
Mellinghoff SC; Panse J; Alakel N; Behre G; Buchheidt D; Christopeit M; Hasenkamp J; Kiehl M; Koldehoff M; Krause SW; Lehners N; von Lilienfeld-Toal M; Löhnert AY; Maschmeyer G; Teschner D; Ullmann AJ; Penack O; Ruhnke M; Mayer K; Ostermann H; Wolf HH; Cornely OA
Ann Hematol; 2018 Feb; 97(2):197-207. PubMed ID: 29218389
[TBL] [Abstract][Full Text] [Related]
38. Micafungin prophylaxis for acute leukemia patients undergoing induction chemotherapy.
Park H; Youk J; Shin DY; Hong J; Kim I; Kim NJ; Lee JO; Bang SM; Yoon SS; Park WB; Koh Y
BMC Cancer; 2019 Apr; 19(1):358. PubMed ID: 30991992
[TBL] [Abstract][Full Text] [Related]
39. The Incidence of Invasive Fungal Infections in Patients With AML Treated With a Hypomethylating Agent.
Ozga M; Huang Y; Blachly JS; Grieselhuber NR; Wall S; Larkin K; Haque T; Walker AR; Bhatnagar B; Behbehani G; Vasu S; Maakaron JE; Lustberg M; Mims AS
Clin Lymphoma Myeloma Leuk; 2021 Jan; 21(1):e76-e83. PubMed ID: 32921593
[TBL] [Abstract][Full Text] [Related]
40. Invasive fungal infection in patients receiving chemotherapy for hematological malignancy: a multicenter, prospective, observational study in China.
Sun Y; Huang H; Chen J; Li J; Ma J; Li J; Liang Y; Wang J; Li Y; Yu K; Hu J; Jin J; Wang C; Wu D; Xiao Y; Huang X
Tumour Biol; 2015 Feb; 36(2):757-67. PubMed ID: 25293517
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
